INS and Hyperglycemia: First-line treatment should potentially include drugs that increase insulin sensitivity, targeting postprandial hyperglycemia as well as the other adverse effects of GCs, such as weight gain, increased fracture risk, and cardiovascular events such as metformin and pioglitazone (407-410), which can be also continued in patients with pre-existing T2D unless there are contraindications.